REQUEST FOR APPLICATIONS
CTSA KL2 Clinical and Translational Scholar Awards

Applications Due by 11:59 pm CST Sunday, September 23, 2018

The Institute for Translational Medicine announces funding for CTSA KL2 Clinical and Translational Scholar Awards that provide substantial salary support (up to $75,000 plus fringe) for faculty-level clinical and translational scientists near the beginning of their investigative careers. Applications are for funding in 2019, with appointments beginning as early as July 1, 2019. Appointments are for two years. Eligible candidates may be from any ITM-affiliated institution (Rush, Loyola, NorthShore, IIT, Advocate), must hold a doctoral degree and must have a faculty-level appointment during the period of support. Graduate students or post-doctoral trainees are not eligible.

For the purposes of this award, and in agreement with the recommendations of the NIH Director's Panel on Clinical Research, (http://www.nih.gov/news/crp/97report/index.htm), patient-oriented research is defined as research conducted with human subjects (or on material of human origin such as tissues, specimens and cognitive phenomena for which an investigator directly interacts with human subjects). This area of research includes 1) mechanisms of human disease; 2) therapeutic interventions; 3) clinical trials; and 4) the development of new technologies. Research topics can relate to any aspect of clinical and/or translational research, relevant to any patient population and disease group, and employing any suitable research approach. However, potential relevance to the understanding or treatment of human disease must be demonstrated.

OVERVIEW OF THE CTSA KL2 MECHANISM

CTSA KL2 Scholars are to be relatively new investigators, at the faculty level of Assistant Professor or Instructor, who are committed to a career in clinical and/or translational research. In certain circumstances, Associate Professors can apply if they are newly entering the field of clinical and translational research. The goal of the CTSA KL2 Scholar mechanism is to produce accomplished clinical/translational researchers capable of utilizing the tools of clinical and/or basic research to improve the understanding or treatment of human disease.

HEALTHY CHICAGO 2.0

In 2016, Mayor Rahm Emanuel and the Chicago Department of Public Health (CDPH) launched Healthy Chicago 2.0, a plan focused on ensuring a city with strong communities and collaborative stakeholders, where all residents enjoy equitable access to resources, opportunities and environments that maximize their health and well-being. Healthy Chicago 2.0 serves as the start for a new movement dedicated to improving health equity and making Chicago a connected, vibrant and healthy city for all residents. As a partner of the CDPH and an institutional citizen of Chicago, the ITM seeks to align its activities and funding support with the goals of the Healthy Chicago 2.0 plan. KL2 Scholars’ Research Projects should align with one of the following Healthy Chicago 2.0 program areas, and applicants should consider how their project will improve Healthy Chicago 2.0 indicators.
• Expanding Partnership and Community Engagement
• Addressing Root Causes of Health (economic development, built environment, transportation, climate change, and housing)
• Addressing Education
• Increasing Access to Health and Human Services
• Promoting Behavioral Health
• Strengthening Child & Adolescent Health
• Chronic Disease- obesity and physical
• Chronic Disease- tobacco
• Preventing and Controlling Chronic Disease
  o obesity
  o tobacco use
  o cancer and chronic disease management
• Reducing the Burden of Infectious Disease
• Reducing Violence
• Utilizing and Maximizing Data and Research

EXPECTATIONS OF CTSA KL2 SCHOLARS

• Candidates are expected to assemble a multidisciplinary mentoring committee of senior advisors/mentors and meet with their mentors regularly.
• All KL2 Scholars are expected to participate in the monthly ITM Clinical Scholar Seminar Series, as well as ITM Outcomes Research Workshops or other ITM educational seminars, as appropriate to their areas of study.
• A crucial expectation of the awardees is that preliminary data will be developed which will serve as the basis for an NIH grant application (or equivalent) in clinical and/or translational research.
• Awardees will be expected to submit reports on a yearly basis or more frequently as requested by ITM leadership.

KL2 SCHOLAR APPLICATION

Applications must be submitted online using the KL2 Career Development Program Application (https://redcap.uchicago.edu/surveys/?s=LRFTEF97LE) by Sunday, September 23, 2018 at 11:59:59 pm. Applications will not be accepted after the deadline, so please start early and plan for questions and last minute submission problems.

Applications must include the following:

1. A full curriculum vitae (not an NIH Biosketch).
2. A one-page description of candidate’s commitment to an academic career in patient-oriented research. Include a description of all professional responsibilities and show their relation to the proposed activities on the career award.
3. A one-page detailed, structured training plan to be undertaken during the appointment period.
4. A seven-page research plan including Specific Aims (1 page) and Research Strategy (6 pages), the latter including Significance, Innovation, Approach, Impact, and Preliminary Studies. In addition (no page restriction), please include Literature Cited and information regarding Human Subjects and Vertebrate Animals as appropriate.
5. A brief (1-2 paragraph) explanation of how the research project aligns with Healthy Chicago 2.0 goals and will improve Healthy Chicago 2.0 indicators.
6. A brief letter from the Department Chair or Section Leader addressing:
a. The candidate’s prospects for development into an independently funded clinical/translational scientist;

b. The Department’s assurance that at least 75% of the candidate’s time will be protected for research career development and devoted to her/his role as a K12 Scholar (at least 50% for surgeons);

c. Names of the proposed mentors who will constitute a multidisciplinary mentoring committee for the Scholar (a minimum of two disciplines must be represented)

7. A brief letter from the candidate’s mentors, indicating their commitment to the candidate and endorsement of the candidate’s training plan.

8. For projects that involve human subjects research, the following documentation must also be included in the application.

   a. While the protocol does not yet have to have IRB approval, the IRB application must have been submitted in AURA. Applicants must list “ISAP” as a reviewing committee in answering question 2.1.2 of your IRB application. The ITM pilot application must list the project’s AURA-IRB number. For applications coming from outside the University of Chicago, a copy of the complete IRB application, including all documents, must be submitted.


   c. Inclusion plans for Women, Minorities and Children

   d. Targeted Enrollment Table or Inclusion Data Record

   e. Data and Safety Monitoring Plan

   f. Proof of Human Subjects Research and Good Clinical Practice training for all study personnel

Projects that are deemed by the IRB to be Exempt must provide a letter of exemption from the IRB, citing the exemption category.

PLEASE NOTE: All applications involving human subjects research must undergo a regulatory review prior to receiving an award. Applicants must have completed an IRB application by the time they submit their pilot application. Failure to provide the requested human subjects research documentation may result in your application being rejected from review.

All uploaded application documents must be in PDF format, with a minimum ½” margins and 11 pt. Font.

Applications by women, underrepresented minorities, individuals from disadvantaged backgrounds, and individuals with disabilities remain a high priority for funding. The academic and intellectual background, motivation, and commitment of the candidate to pursue clinical and/or translational research will be evaluated.

The criteria for selecting awardees will include assessment of the candidate’s potential, the dedication to clinical and/or translational research, and the degree of support from the Department.

Application deadline is 11:59:59 pm CST, Sunday, September 23, 2018.